Meristem Family Wealth’s Harvard Bioscience HBIO Stock Holding History

Meristem Family Wealth’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,344	Closed	-$71K	–	140
2018 Q3	$71K	Hold	1,344	–	–	0.02%	143
2018 Q2	$72K	Hold	1,344	–	–	0.03%	140
2018 Q1	$67K	Hold	1,344	–	–	0.02%	131
2017 Q4	$44K	Buy	1,344 +107	+9%	+$3.61K	0.02%	123
2017 Q3	$46K	Hold	1,237	–	–	0.02%	112
2017 Q2	$32K	Hold	1,237	–	–	0.01%	104
2017 Q1	$32K	Hold	1,237	–	–	0.01%	105
2016 Q4	$38K	Hold	1,237	–	–	0.02%	107
2016 Q3	$34K	Hold	1,237	–	–	0.01%	115
2016 Q2	$35K	Buy	+1,237	New	+$39.3K	0.02%	105

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Meristem Family Wealth's HBIO Position: Q4 2018 in Review

Meristem Family Wealth sold out of Harvard Bioscience (HBIO) in Q4 2018, closing a stake of 1,344 shares — an estimated $71K sold.

Meristem Family Wealth first reported a position in HBIO in Q2 2016 and held it in 10 quarters. The position peaked at $72K in Q2 2018. 80 funds tracked by Wall St. Rank hold HBIO as of Q4 2018.

Meristem Family Wealth reported no remaining Harvard Bioscience position as of Q4 2018 after selling out during the quarter.
Meristem Family Wealth sold 1,344 Harvard Bioscience shares in Q4 2018, an estimated $71K.
Meristem Family Wealth first reported a position in Harvard Bioscience in Q2 2016 and held it in 10 quarters.
Meristem Family Wealth's Harvard Bioscience position peaked at $72K in Q2 2018.
80 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2018.

Based on Meristem Family Wealth's 13F filing for Q4 2018, filed 7 Feb 2019.